NASDAQ:KLDO

Kaleido Biosciences Stock Forecast, Price & News

$7.07

-0.44 (-5.86 %)

(As of 04/9/2021 12:00 AM ET)

Add

Compare

Today's Range

$6.94

Now: $7.07▼

$7.41

50-Day Range

$7.20

MA: $9.33▼

$10.99

52-Week Range

$5.04

Now: $7.07▼

$20.50

Volume17,311 shs

Average Volume299,082 shs

Market Capitalization$300.24 million

P/E RatioN/A

Dividend YieldN/A

Beta0.02

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:KLDO

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.kaleido.com

Phone617 674 9000

Employees82

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares42,467,000

Market Cap$300.24 million

Next Earnings Date5/13/2021 (Estimated)

OptionableNot Optionable

Headlines

Kaleido Biosciences, Inc. (NASDAQ:KLDO) Given Consensus Recommendation of "Hold" by Analysts
April 7, 2021 | americanbankingnews.com

CytoDyn (CYDY) Files New Protocol With FDA for COVID-19 Study
April 1, 2021 | finance.yahoo.com

Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer
March 30, 2021 | finance.yahoo.com

Kaleido (KLDO) Reports Positive Results from COVID-19 Study
March 25, 2021 | finance.yahoo.com

The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping
March 24, 2021 | msn.com

Kaleido: KB109 Shows Favorable Safety, Tolerability Profile In Non-IND Study
March 24, 2021 | nasdaq.com

Kaleido Biosciences Stock Is Trading Higher On Positive KB109 Data In COVID-19 Study
March 24, 2021 | markets.businessinsider.com

Kaleido Biosciences Reports Positive Results from Non-IND Study Demonstrating a Reduction in COVID-19 Related Healthcare Utilization and Recovery Time in Patients with Mild-to-Moderate COVID-19 and One or More Comorbidity
March 24, 2021 | finance.yahoo.com

Kaleido Biosciences says oral drug cuts COVID-19 recovery time, hospitalizations
March 24, 2021 | finance.yahoo.com

Kaleido Biosciences to Present at Chardan’s 3rd Annual Microbiome Medicines Summit
March 1, 2021 | finance.yahoo.com

Kaleido Biosciences (KLDO) Sees Hammer Chart Pattern: Time to Buy?
February 24, 2021 | nasdaq.com

Kaleido Biosciences Announces the Exercise of the Underwriters' Option to Purchase Additional Shares of Common Stock
February 12, 2021 | marketwatch.com

Kaleido Biosciences Announces the Exercise of the Underwriters’ Option to Purchase Additional Shares of Common Stock
February 11, 2021 | finance.yahoo.com

What Is The Ownership Structure Like For Kaleido Biosciences, Inc. (NASDAQ:KLDO)?
February 9, 2021 | finance.yahoo.com

Kaleido Biosciences to Present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” Conference
January 20, 2021 | finance.yahoo.com

Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19
January 14, 2021 | finance.yahoo.com

Kaleido Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 5, 2021 | finance.yahoo.com

Kaleido Biosciences Announces Completion of Enrollment of 350 Subjects in Controlled Study of KB109 in the Treatment of Mild-to-Moderate COVID-19
January 4, 2021 | finance.yahoo.com

Kaleido Biosciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 24, 2020 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.84 out of 5 stars

Medical Sector

115th out of 2,011 stocks

Biotechnology Industry

11th out of 143 stocks

3.3 Analyst's Opinion

Consensus Rating
Kaleido Biosciences has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $17.90, Kaleido Biosciences has a forecasted upside of 153.2% from its current price of $7.07.
Amount of Analyst Coverage
Kaleido Biosciences has only been the subject of 4 research reports in the past 90 days.

2.0 Community Rank

Outperform Votes
Kaleido Biosciences has received 44 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Kaleido Biosciences has received 68 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Kaleido Biosciences has received 60.71% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Kaleido Biosciences and other stocks. Vote “Outperform” if you believe KLDO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KLDO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Kaleido Biosciences does not currently pay a dividend.
Dividend Growth
Kaleido Biosciences does not have a long track record of dividend growth.

3.3 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kaleido Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,472,500.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 10.00% of the stock of Kaleido Biosciences is held by insiders.
Percentage Held by Institutions
79.91% of the stock of Kaleido Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Kaleido Biosciences are expected to grow in the coming year, from ($2.31) to ($1.78) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kaleido Biosciences is -2.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kaleido Biosciences is -2.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

$7.07

-0.44 (-5.86 %)

(As of 04/9/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive KLDO News and Ratings via Email

Sign-up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter.

Kaleido Biosciences (NASDAQ:KLDO) Frequently Asked Questions

Is Kaleido Biosciences a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last twelve months. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Kaleido Biosciences stock.
View analyst ratings for Kaleido Biosciences or view top-rated stocks.

What stocks does MarketBeat like better than Kaleido Biosciences?

Wall Street analysts have given Kaleido Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Kaleido Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Kaleido Biosciences' next earnings date?

Kaleido Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Kaleido Biosciences.

How were Kaleido Biosciences' earnings last quarter?

Kaleido Biosciences, Inc. (NASDAQ:KLDO) announced its earnings results on Tuesday, March, 2nd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.16. The firm earned $0.24 million during the quarter.
View Kaleido Biosciences' earnings history.

How has Kaleido Biosciences' stock been impacted by Coronavirus (COVID-19)?

Kaleido Biosciences' stock was trading at $5.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KLDO shares have increased by 27.6% and is now trading at $7.07.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for KLDO?

6 brokerages have issued 1-year target prices for Kaleido Biosciences' stock. Their forecasts range from $12.00 to $22.00. On average, they expect Kaleido Biosciences' share price to reach $17.90 in the next twelve months. This suggests a possible upside of 153.2% from the stock's current price.
View analysts' price targets for Kaleido Biosciences or view top-rated stocks among Wall Street analysts.

Who are Kaleido Biosciences' key executives?

Kaleido Biosciences' management team includes the following people:

Mr. Daniel L. Menichella B.A., M.B.A., Pres, CEO & Director (Age 62, Pay $525.7k)
Dr. Geoffrey von Maltzahn Ph.D., Co-Founder & Director (Age 40)
Mr. William E. Duke Jr., Chief Financial Officer (Age 49, Pay $672.87k)
Dr. Katharine Knobil M.D., Consultant (Age 56, Pay $695.78k)
Dr. Johan van Hylckama Vlieg Ph.D., Chief Scientific Officer (Age 52)
Mr. Jerald Korn J.D., Chief Admin. Officer, Gen. Counsel & Corp. Sec. (Age 42)
Ms. Susan Stewart J.D., Chief Regulatory Affairs Officer (Age 59)
Ms. Clare Fisher, Chief Bus. Officer

Who are some of Kaleido Biosciences' key competitors?

Some companies that are related to Kaleido Biosciences include PureTech Health (PRTC), Vor Biopharma (VOR), 4D Molecular Therapeutics (FDMT), Connect Biopharma Holdings Limited American Depositary Shares (CNTB), iTeos Therapeutics (ITOS), Pharvaris B.V. (PHVS), Gracell Biotechnologies (GRCL), Pharming Group (PHAR), Bolt Biotherapeutics (BOLT), Oxford Biomedica (OXB), Finch Therapeutics Group (FNCH), Aptose Biosciences (APS), Biotest Aktiengesellschaft (BIO), Burcon NutraScience (BU) and Gemini Therapeutics (GMTX).
View all of KLDO's competitors.

What other stocks do shareholders of Kaleido Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Stoke Therapeutics (STOK).

When did Kaleido Biosciences IPO?

(KLDO) raised $101 million in an IPO on Thursday, February 28th 2019. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Kaleido Biosciences' stock symbol?

Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."

How do I buy shares of Kaleido Biosciences?

Shares of KLDO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kaleido Biosciences' stock price today?

One share of KLDO stock can currently be purchased for approximately $7.07.

How much money does Kaleido Biosciences make?

Kaleido Biosciences has a market capitalization of $300.24 million.

How many employees does Kaleido Biosciences have?

Kaleido Biosciences employs 82 workers across the globe.

What is Kaleido Biosciences' official website?

The official website for Kaleido Biosciences is www.kaleido.com.

How can I contact Kaleido Biosciences?

The company can be reached via phone at 617 674 9000.

This page was last updated on 4/12/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here